EORTC-1203-GITCG - the “INNOVATION”-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: a randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer group

Background 10–20% of patients with gastric cancer (GC) have HER2+ tumors. Addition of trastuzumab (T) to cisplatin/fluoropyrimidine-based chemotherapy (CT) improved survival in metastatic, HER2+ GC. When pertuzumab (P) was added to neoadjuvant T and CT, a significant increase in histopathological co...

Full description

Saved in:

Bibliographic Details
Published in:	BMC Cancer Vol. 19; no. 1; pp. 494 - 9
Main Authors:	Wagner, Anna Dorothea, Grabsch, Heike I., Mauer, Murielle, Marreaud, Sandrine, Caballero, Carmela, Thuss-Patience, Peter, Mueller, Lothar, Elme, Annelie, Moehler, Markus Hermann, Martens, Uwe, Kang, Yoon-Koo, Rha, Sun Young, Cats, Annemieke, Tokunaga, Masanori, Lordick, Florian
Format:	Journal Article
Language:	English
Published:	London Springer Science and Business Media LLC 24.05.2019 BioMed Central BioMed Central Ltd Springer Nature B.V BMC
Subjects:	Adenocarcinoma Adenocarcinoma - drug therapy Adenocarcinoma - mortality Adult Aged Aged, 80 and over Antibodies, Monoclonal, Humanized Antibodies, Monoclonal, Humanized - administration & dosage Antibodies, Monoclonal, Humanized - therapeutic use Antineoplastic Agents Antineoplastic Agents - therapeutic use Antineoplastic Agents, Immunological Antineoplastic Agents, Immunological - administration & dosage Antineoplastic Agents, Immunological - therapeutic use Antineoplastic Combined Chemotherapy Protocols Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biomedical and Life Sciences Biomedicine BREAST-CANCER Cancer Cancer metastasis Cancer patients Cancer Research Cancer therapies Cancer treatment CAPECITABINE Capecitabine - therapeutic use Chemotherapy Cisplatin Cisplatin - therapeutic use Clinical trials Comparative analysis DOCETAXEL Dosage and administration Drug delivery Drug therapy Epidermal growth factor ErbB-2 protein Esophageal cancer Esophageal Neoplasms Esophageal Neoplasms - drug therapy Esophageal Neoplasms - mortality Esophagogastric Junction Esophagogastric Junction - pathology Esophagus Female Fluorouracil Fluorouracil - therapeutic use Follow-Up Studies Gastric cancer Gastric cancer; Gastro-esophageal junction cancer; HER2; Perioperative chemotherapy; Pertuzumab; Trastuzumab Gastro-esophageal junction cancer Gastrointestinal cancer Gastrointestinal system Gastrointestinal tract Health Promotion and Disease Prevention HER2 Humans Immunohistochemistry Immunotherapy Intestine Labels Male Medical and radiation oncology Medicine/Public Health Metastases Metastasis Middle Aged Monoclonal antibodies NEOADJUVANT CHEMOTHERAPY Neoadjuvant Therapy Neoplasms. Tumors. Oncology. Including cancer and carcinogens Netherlands Oncology OPEN-LABEL OXALIPLATIN Patients Perioperative chemotherapy Perioperative Period Pertuzumab Progression-Free Survival Prospective Studies RC254-282 Receptor, ErbB-2 Receptor, ErbB-2 - metabolism REGRESSION Republic of Korea Response rates Stomach cancer Stomach Neoplasms Stomach Neoplasms - drug therapy Stomach Neoplasms - mortality Studies Study Protocol SURGERY Surgical Oncology Surgical outcomes Targeted cancer therapy Taxotere Trastuzumab Trastuzumab - administration & dosage Trastuzumab - therapeutic use Treatment Outcome Tumors Young Adult Netherlands Republic of Korea Asia Europe Perioperative chemotherapy Pertuzumab HER2 Gastric cancer Gastro-esophageal junction cancer Trastuzumab
ISSN:	1471-2407, 1471-2407
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!